Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Atezolizumab; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Procedure: Lumpectomy; Procedure: Mastectomy; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified September 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Breast Lumpectomy | Cancer | Cancer & Oncology | Carcinoma | HER2 | Lumpectomy | Mastectomy | Research